Posted by Michael Wonder on 07 Apr 2017
Others to follow Enbrel biosimilar launch in Australia, Merck says
5 April 2017 - US pharma giant Merck has pledged to follow up the launch of a biosimilar etanercept in Australia with more copycat biologics, promising to spare the country’s Pharmaceutical Benefits Scheme from paying the full price of the reference products.
The original version of etanercept, which is indicated for rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis and non-radiographic axial spondyloarthritis, is sold (outside Australia) by US biotech major Amgen under the name Enbrel, while Merck has called its biosimilar Brenzys
